PolyPeptide Group AG (SIX: PPGN), a specialized global CDMO for peptide-based active pharmaceutical ingredients, announced that its shareholders approved all proposals put forward by the Board of Directors at the Company's fifth annual General Meeting (AGM 2026) with a large majority. The meeting, held at the Chollerhalle in Zug, saw 80.85% of issued registered shares represented, totaling 26,780,855 shares with voting rights.
All six members of the Board of Directors proposed for re-election were appointed for a term ending at the conclusion of the next annual General Meeting in 2027. Peter Wilden was re-elected as Chair of the Board of Directors, and Philippe Weber and Peter Wilden were each individually re-elected as members of the Remuneration and Nomination Committee for the same term. The re-election of statutory auditors and independent proxy was also approved, along with the maximum aggregate compensation for the Board and Executive Committee. Shareholders granted discharge to all Board and Executive Committee members for their activities in the financial year 2025 and approved the management report, statutory financial statements, consolidated financial statements, and the report on non-financial matters for 2025. The Remuneration Report 2025 was approved in a separate consultative vote.
This strong shareholder support underscores confidence in PolyPeptide's strategic direction as it continues to capitalize on the fast-growing market for peptide-based therapies, including significant exposure to metabolic diseases such as GLP-1. The company's global network of six GMP-certified facilities in Europe, the U.S., and India positions it to serve customers from pre-clinical to commercial stages. The minutes of the AGM 2026 will be available within 15 days on the company's website. The next annual General Meeting is scheduled for April 7, 2027.
